[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
December 2, 1974

Aspirin and Aspirin Products

JAMA. 1974;230(9):1311. doi:10.1001/jama.1974.03240090051031

An earlier editorial in The Journal, "Aspirin Can Be Dangerous" (228:609, 1974), called attention to the risk of administering aspirin or aspirin-containing compounds to patients with a hemorrhagic diathesis, especially hemophilia, or to patients with a propensity for or a history of peptic ulcer. That editorial was based in part on a report by Binder et al1 who demonstrated that the bleeding time is not prolonged after oral administration of propoxyphene hydrochloride (Darvon), 64 mg; choline salicylate (Arthropan), 870 mg; pentazocine hydrochloride (Talwin), 50 mg; prednisone, 30 mg; and codeine, 30 mg. The authors concluded that these five drugs could be used safely for their analgesic or anti-inflammatory action in hemophilia.

In the course of their report, Binder and his co-workers listed more than 60 aspirin-containing drug products, many of which do not hint by their brand names that they contain aspirin and can be purchased without a prescription.